Last reviewed · How we verify
Neu2000KWL group — Competitive Intelligence Brief
phase 3
NMDA receptor antagonist with antioxidant properties
NMDA receptor; free radical scavenger
Neurology
Small molecule
Live · refreshed every 30 min
Target snapshot
Neu2000KWL group (Neu2000KWL group) — GNT Pharma. Neu2000KWL is a neuroprotective agent designed to reduce excitotoxic and oxidative damage in the central nervous system.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Neu2000KWL group TARGET | Neu2000KWL group | GNT Pharma | phase 3 | NMDA receptor antagonist with antioxidant properties | NMDA receptor; free radical scavenger |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (NMDA receptor antagonist with antioxidant properties class)
- GNT Pharma · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Neu2000KWL group CI watch — RSS
- Neu2000KWL group CI watch — Atom
- Neu2000KWL group CI watch — JSON
- Neu2000KWL group alone — RSS
- Whole NMDA receptor antagonist with antioxidant properties class — RSS
Cite this brief
Drug Landscape (2026). Neu2000KWL group — Competitive Intelligence Brief. https://druglandscape.com/ci/neu2000kwl-group. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing